BioSpace News Archive

DTx Pharma, Inc. (DTx), a privately-held California biotechnology company developing novel RNA-based therapeutics to treat the genetic drivers of disease, today announced the appointment of Dr. Michael Huang as its Chief Medical Officer.

Axsome Therapeutics, Inc. today announced the publication on May 30, 2022 of the results from the pivotal GEMINI Phase 3 clinical trial of AXS-05 (dextromethorphan-bupropion) in major depressive disorder (MDD).

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the publication on May 30, 2022 of the results from the pivotal GEMINI Phase 3 clinical trial of AXS-05 (dextromethorphan-bupropion) in major depressive disorder (MDD).

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has approved a label extension for Evrysdi® to include babies under two months old with spinal muscular atrophy.

Celyad Oncology SA, a clinical-stage biotechnology company focused on the discovery and the development of Chimeric Antigen Receptor T cell therapies for cancer, announced that 350 registered shares benefit from a double voting right as of May 25, 2022.

STipe Therapeutics announced the strengthening of its leadership team with the appointment of Dr Richard Sainson as Chief Scientific Officer, effective June 6, 2022.

Memo Therapeutics AG, an innovator in the field of antibody discovery and development, announced the initiation of a phase 1 clinical study targeting BK polyomavirus infection in renal transplant patients.

International medical imaging IT and cybersecurity company Sectra and UniHA, a cooperative of French public hospitals, have signed a framework agreement for Sectra Digital Pathology.

TScan Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate TSC-101 for the treatment of patients with hematologic malignancies who are undergoing allogeneic hematopoietic cell transplantation (HCT).

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the promotion of Cofounder Cam Gallagher, MBA, to President.